Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

Part of paid clinical trials in Sacramento, California.

Sponsor
Lynch Regenerative Medicine
Study ID
NCT07718347
Status
Recruiting
Apply to this trial

Conditions

  • Aging
  • Aging Mid-Face
  • Immediate Post-Treatment Care

Eligibility Criteria

Sex
ALL
Age
40 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF). — OTHER
    To compare time to appearance-based recovery and subject satisfaction between ariessence and standard of care groups using standardized photographs and investigator/subject ratings for tolerability and satisfaction

Study Details

ariessence is intended to be used as a viscous, leave-on solution designed for topical application to the face. It is intended to be used following non-medical cosmetic procedures, performed by licensed healthcare professionals to enhance comfort and maintain skin hydration. This study is designed to be a multi-center, post-market cosmetic evaluation of ariessence applied to the full face after an ablative laser procedure to evaluate improvements in procedure tolerability and improvements in the appearance of the skin, compared to an emollient control.

Key Dates

First listed
Jul 21, 2026
Start date
Apr 16, 2026
Status verified
Jul 2026
Primary completion
Nov 30, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
21 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: ariessence pure PDGF+
    ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).
  • Placebo Comparator: standard of care
    The non-treatment control group will be treated only with the SOC (Aquaphor or equivalent emoilment) and post-procedure instructions.

Primary Outcome Measure

Clinical Measures [ Time Frame: Baseline (Day 0) through Day 84 (End of Study). ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Laser & Skin Surgery Medical GroupSacramentoCalifornia95816
Suzanne Kilmer, MD
[email protected]
916-456-0400
The Practice of Brian S. Biesman, MDNashvilleTennessee37203
Brian S Biesman, MD
[email protected]
615-329-1110

Find similar trials in Sacramento, CA

By research site
Laser & Skin Surgery Medical Group· Sacramento, CAThe Practice of Brian S. Biesman, MD· Nashville, TN

Related Studies